Creating a new nanodrug to treat endometriosis
Development of anti-inflammatory nanodrug for endometriosis treatment
This study is testing a new tiny drug made from cerium oxide that aims to help women with endometriosis by reducing pain and lesions while causing fewer side effects than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10881767 on NIH RePORTER |
What this research studies
This research focuses on developing a targeted nanodrug that aims to treat endometriosis, a condition affecting many women and often leading to chronic pain and infertility. The approach involves using cerium oxide nanoparticles, which have anti-inflammatory properties, to specifically target and reduce endometriotic lesions while minimizing side effects. By utilizing advanced imaging techniques, the researchers plan to ensure that the nanodrug effectively reaches the affected tissues. The goal is to provide a safer and more effective treatment option compared to current hormonal therapies and surgical interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are women of reproductive age who are diagnosed with endometriosis and experience chronic pelvic pain or infertility.
Not a fit: Patients who do not have endometriosis or those who are not of reproductive age may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a novel, non-hormonal treatment for endometriosis that alleviates pain and reduces lesions with fewer side effects.
How similar studies have performed: Previous research has shown promise in using targeted nanodrugs for treating various conditions, suggesting potential success for this novel approach in endometriosis.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Kim, Taeho — Michigan State University
- Study coordinator: Kim, Taeho
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.